2026-09-19T06:52:28Zhttps://dspace.mit.edu/server/oai/request

oai:dspace.mit.edu:1721.1/1128642026-06-06T01:04:11Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023

Bruce C. Arntzen. Nabiyeva, Aisha Wu, David Z. Y Massachusetts Institute of Technology. Supply Chain Management Program. Massachusetts Institute of Technology. Supply Chain Management Program n-us--- 2017-12-20T18:15:17Z 2017-12-20T18:15:17Z 2017 2017 http://hdl.handle.net/1721.1/112864 1014332427 Thesis: M. Eng. in Supply Chain Management, Massachusetts Institute of Technology, Supply Chain Management Program, 2017. Cataloged from PDF version of thesis. Includes bibliographical references (pages 48-49). This thesis explores the impact of the Drug Supply Chain Security Act (DSCSA) on various stakeholders in the pharmaceutical supply chain. Specific attention has been dedicated to the impact on manufacturers and distributors/retailers. Although various interpretations of the DSCSA are possible, this thesis takes the perspective of a centralized data model, and tests the feasibility of implementing a centralized database under both data nesting and unit level relational models. This is in contrast to the decentralized system, which is further explored in the partner thesis, Impact of Drug Supply Chain Security Act on US pharmaceutical industry under decentralized information flow (Chang & Mohan, 2017). Both quantitative and qualitative analysis are employed in this thesis. Quantitative analysis was conducted using publically available industry data, from which the impact on overall supply chain costs was modeled. Qualitative analysis consisted of stakeholder interviews, process mapping, and time studies to determine the extent of process changes and what they should look like to conform to DSCSA. After accounting for the current state of implementation, as well as real-world constraints, the findings indicate that the best-practice scenario for Manufacturers and Distributors/Retailers to conform to DSCSA is one using a Centralized data model and nested linked-pedigrees. Although this option is estimated to be 67% costlier than the least expensive scenario, it offers a more robust and secure data model that allows for better long-term scalability. Implementation and cost concerns are also discussed in the conclusion to elaborate on trends and considerations in choosing the appropriate Serialization scenario to pursue. by Aisha Nabiyeva and David Z.Y. Wu. M.Eng. in Supply Chain Management 49 pages eng Massachusetts Institute of Technology MIT theses may be protected by copyright. Please reuse MIT thesis content according to the MIT Libraries Permissions Policy, which is available through the URL provided. http://dspace.mit.edu/handle/1721.1/7582 Supply Chain Management Program. Serialization of prescription drugs in the USA : a centralized view Serialization of prescription drugs in the United States of America : a centralized view Thesis application/pdf false Publication unknown unknown <Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="3287d169-d371-4742-b658-551b18f752bd"> <Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type> <Language>eng</Language> <Title>Serialization of prescription drugs in the USA : a centralized view</Title> <Subtitle>Serialization of prescription drugs in the United States of America : a centralized view</Subtitle> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2017</PublicationDate> <Authors> <Author> <DisplayName>Nabiyeva, Aisha</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Wu, David Z. Y</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <DisplayName>Massachusetts Institute of Technology</DisplayName> <OrgUnit /> </Publisher> </Publishers> <License>http://dspace.mit.edu/handle/1721.1/7582</License> <Keyword>Supply Chain Management Program.</Keyword> <Abstract>This thesis explores the impact of the Drug Supply Chain Security Act (DSCSA) on various stakeholders in the pharmaceutical supply chain. Specific attention has been dedicated to the impact on manufacturers and distributors/retailers. Although various interpretations of the DSCSA are possible, this thesis takes the perspective of a centralized data model, and tests the feasibility of implementing a centralized database under both data nesting and unit level relational models. This is in contrast to the decentralized system, which is further explored in the partner thesis, Impact of Drug Supply Chain Security Act on US pharmaceutical industry under decentralized information flow (Chang &amp; Mohan, 2017). Both quantitative and qualitative analysis are employed in this thesis. Quantitative analysis was conducted using publically available industry data, from which the impact on overall supply chain costs was modeled. Qualitative analysis consisted of stakeholder interviews, process mapping, and time studies to determine the extent of process changes and what they should look like to conform to DSCSA. After accounting for the current state of implementation, as well as real-world constraints, the findings indicate that the best-practice scenario for Manufacturers and Distributors/Retailers to conform to DSCSA is one using a Centralized data model and nested linked-pedigrees. Although this option is estimated to be 67% costlier than the least expensive scenario, it offers a more robust and secure data model that allows for better long-term scalability. Implementation and cost concerns are also discussed in the conclusion to elaborate on trends and considerations in choosing the appropriate Serialization scenario to pursue.</Abstract> <Access xmlns="http://purl.org/coar/access_right" > </Access> </Publication>